National and international developments in cancer, health and policy. Produced in collaboration with the Press Association unless otherwise stated.
A hormone therapy has been rejected for some adults with newly-diagnosed, advanced prostate cancer.
New clinical trial results show that adding rituximab to standard chemotherapy could improve survival for some children with non-Hodgkin lymphoma.
A new immunotherapy treatment has been recommended by the National Institute for Health and Care Excellence (NICE) for some adults with small cell lung cancer.
Atezolizumab used in combination with nab-paclitaxel is the first immunotherapy available for triple negative breast cancer.